Text Size

Protocol to Obtain Blood Samples for Leukemia Research

This study is currently recruiting participants.
Verified February 2013 by Dartmouth-Hitchcock Medical Center
Sponsor:
Information provided by (Responsible Party):
Dartmouth-Hitchcock Medical Center
ClinicalTrials.gov Identifier:
NCT00889031
First received: April 24, 2009
Last updated: February 13, 2013
Last verified: February 2013
History of Changes
  Purpose

The purpose of this study is to collect a blood sample in patients with Chronic Lymphocytic Leukemia (CLL).


Condition Intervention
Chronic Lymphocytic Leukemia
 Other: No Intervention

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Protocol to Obtain Blood Samples for Leukemia Research

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Dartmouth-Hitchcock Medical Center:

Primary Outcome Measures:
  • To determine the frequency with which CLL cells incubated ex vivo with vincristine undergo rapid interphase apoptosis. [ Time Frame: 2 Years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • To determine whether suppression or inhibition of BCL2 family members can acutely sensitize CLL cells to vincristine. [ Time Frame: 2 Years ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA

10cc of peripheral blood.


Estimated Enrollment: 50
Study Start Date: April 2009
Estimated Study Completion Date: April 2015
Estimated Primary Completion Date: April 2015 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
No Treatment Other: No Intervention
Patients with Chronic Lymphocytic Leukemia (CLL)
Other Name: No Intervention

Detailed Description:

The blood sample will be used in the laboratory to perform studies focusing on Chronic Lymphocytic Leukemia (CLL).

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients at Dartmouth-Hitchcock Medical Center's Norris Cotton Cancer Center

Criteria

Inclusion Criteria:

  • Patients undergoing routine blood draws as part of their ongoing follow-up for Chronic Lymphocytic Leukemia (CLL) at the Norris Cotton Cancer Center of DHMC.

Exclusion Criteria:

  • Patients who have received cytotoxic drug, oral or intravenous steroid or targeted antibody therapy for CLL or other disease process within the past 6 months are excluded. Use of intravenous immunoglobulin (IVIg) is not a reason for exclusion.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00889031

Contacts
Contact: Research Nurse 800-639-6918 cancer.research.nurse@dartmouth.edu
Contact: Nancy Rollings 603-650-5135 Nancy.J.Rollings@Hitchcock.org

Locations
United States, New Hampshire
Dartmouth-Hitchcock Medical Center Recruiting
Lebanon, New Hampshire, United States, 03756
Contact: Research Nurse     800-639-6918     cancer.research.nurse@dartmouth.edu    
Contact: Nancy Rollings     603-650-5135     Nancy.J.Rollings@Hitchcock.org    
Principal Investigator: Christopher H Lowrey            
Sponsors and Collaborators
Dartmouth-Hitchcock Medical Center
Investigators
Principal Investigator: Christopher H Lowrey, MD Dartmouth-Hitchcock Medical Center
  More Information

Publications:

Responsible Party: Dartmouth-Hitchcock Medical Center
ClinicalTrials.gov Identifier: NCT00889031     History of Changes
Other Study ID Numbers: D0905
Study First Received: April 24, 2009
Last Updated: February 13, 2013
Health Authority: United States: Institutional Review Board

Keywords provided by Dartmouth-Hitchcock Medical Center:
CLL

Additional relevant MeSH terms:
Leukemia
Leukemia, Lymphocytic, Chronic, B-Cell
Leukemia, Lymphoid
Neoplasms by Histologic Type
Neoplasms
 Leukemia, B-Cell
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases

ClinicalTrials.gov processed this record on May 23, 2013